Calculation of PandP_ and T_ odd effects in $"" sup 205_TIF including electron correlation

A method and codes for two-step correlation calculation of heavy-atom molecules have been developed, employing the generalized relativistic effective core potential and relativistic coupled cluster (RCC) methods at the first step, followed by nonvariational one-center restoration of proper four-component spinors in the heavy cores. Electron correlation is included for the first time in an ab initio calculation of the interaction of the permanent P,T-odd proton electric dipole moment with the internal electromagnetic field in a molecule. The calculation is performed for the ground state of TlF at the experimental equilibrium, R_e=2.0844 A, and at R=2.1 A, with spin-orbit and correlation effects included by RCC. Calculated results with single cluster amplitudes only are in good agreement (3% and 1%) with recent Dirac-Hartree-Fock (DHF) values of the magnetic parameter M; the larger differences occurring between present and DHF volume parameter (X) values, as well as between the two DHF calculations, are explained. Inclusion of electron correlation by GRECP/RCC with single and double excitations has a major effect on the P,T-odd parameters, decreasing M by 17% and X by 22%.Comment: 5 pages, REVTeX4 style Accepted for publication in Phys.Rev.Letter

The influence of electrolytes of the ions and the inhibitor on the activity of total atpase of erythrocytes of broiler chickens

The total ATPase activity of erythrocytes of broiler chickens depends on the concentration of ions Na+ and K+. The ATPase activity at 76.5% due to magnesium ions, 96.5% of the sodium ions and 47,6% of potassium ions. Maximum ATPase activity was observed in incubation medium containing ions: Na+ 120 mmol/ml, K+ 20 mmol/ml; Mg2+ - 3.0 mmol/ml and was of 9,24 ±0,23 nmol •mg protein-1•min-1. The ATPase activity has no effect of the specific inhibitor – strophanthin-K in the concentration range of 0-100 mg•l-1 in the medium containing ions Na+ and K+, and in an environment without them.The total ATPase activity of erythrocytes of broiler chickens depends on the concentration of ions Na + and K

Enhancement of the electric dipole moment of the electron in BaF molecule

We report results of ab initio calculation of the spin-rotational Hamiltonian parameters including P- and P,T-odd terms for the BaF molecule. The ground state wave function of BaF molecule is found with the help of the Relativistic Effective Core Potential method followed by the restoration of molecular four-component spinors in the core region of barium in the framework of a non-variational procedure. Core polarization effects are included with the help of the atomic Many Body Perturbation Theory for Barium atom. For the hyperfine constants the accuracy of this method is about 5-10%.Comment: 8 pages, REVTEX, report at II International Symposium on Symmetries in Subatomic Physics, Seattle 199

Enhancement of the electric dipole moment of the electron in PbO

The a(1) state of PbO can be used to measure the electric dipole moment of the electron d_e. We discuss a semiempirical model for this state, which yields an estimate of the effective electric field on the valence electrons in PbO. Our final result is an upper limit on the measurable energy shift, which is significantly larger than was anticipated earlier: $2|W_d|d_e \ge 2.4\times 10^{25} \textrm{Hz} [ \frac{d_e}{e \textrm{cm}} ]$.Comment: 4 pages, revtex4, no figures, submitted to PR

Measurement of the electron's electric dipole moment using YbF molecules: methods and data analysis

We recently reported a new measurement of the electron's electric dipole moment using YbF molecules [Nature 473, 493 (2011)]. Here, we give a more detailed description of the methods used to make this measurement, along with a fuller analysis of the data. We show how our methods isolate the electric dipole moment from imperfections in the experiment that might mimic it. We describe the systematic errors that we discovered, and the small corrections that we made to account for these. By making a set of additional measurements with greatly exaggerated experimental imperfections, we find upper bounds on possible uncorrected systematic errors which we use to determine the systematic uncertainty in the measurement. We also calculate the size of some systematic effects that have been important in previous electric dipole moment measurements, such as the motional magnetic field effect and the geometric phase, and show them to be negligibly small in the present experiment. Our result is consistent with an electric dipole moment of zero, so we provide upper bounds to its size at various confidence levels. Finally, we review the prospects for future improvements in the precision of the experiment.Comment: 35 pages, 15 figure

Регистрация неоригинальных биотерапевтических (биоподобных) препаратов в США

European competent authorities began to elaborate scientific principles of development of non-innovator biotherapeutic (biosimilar) products in the early noughties, and in 2009 these principles were approved at the WHO International Conference in Seoul gathering participants from countries with a well-developed pharmaceutical industry. The USA adopted the law on biosimilar products in 2012, it was based on the documents and recommendations prepared by the EMA and approved by the WHO. In 2015, the FDA published the new revised versions of the guidelines dealing with biosimilar products. The US regulatory requirements for development and authorisation of biosimilar products are based on a step-by-step comparative assessment of biosimilar and innovator products in terms of their quality, efficacy, and safety in accordance with the WHO/EMA recommendations. At the same time the US regulatory requirements differ from those of other national authorities, including EMA (WHO), when it comes to the design of comparative quality studies (studies of products’ physicochemical and biological properties), the assignment of International Non-Proprietary Names and the interchangeability of biosimilar products.Подготовка научных принципов разработки неоригинальных биотерапевтических (биоподобных, биоаналоговых) препаратов была начата в Европе в начале 2000-х гг., в 2009 г. они были утверждены на международной конференции ВОЗ в Сеуле с участием стран с развитой фарминдустрией. В США закон о биоподобных препаратах принят в 2012 г., за основу были взяты документы и рекомендации, подготовленные ЕМА и одобренные ВОЗ. В 2015 г. FDA опубликовало очередную редакцию основных документов, касающихся биоподобных препаратов. В основе нормативных требований США по разработке и регистрации биоподобных препаратов лежит пошаговая сравнительная оценка биоподобного и оригинального препаратов по атрибутам качества, эффективности и безопасности в соответствии с рекомендациями ВОЗ/ЕМА. При этом по таким вопросам, как дизайн сравнительных исследований качества (физико-химических и биологических свойств), присвоение Международного непатентованного наименования и взаимозаменяемость биоподобных препаратов, нормативные требования США отличаются от национальных рекомендаций других стран, в том числе ЕМА (ВОЗ)

Лекарственные препараты фактора VIII, актуальные вопросы разработки, клинического исследования и применения (часть 2)

Continuous replacement therapy with clotting factor products can lead to serious complications in haemophilia A patients. One of potential reasons of such complications is an undesirable immune response to a blood clotting factor VIII (FVIII) product, which undermines the treatment effectiveness. The aim of the study was to systematise and summarise data on undesirable immunogenicity of plasma-derived and recombinant FVIII products, formation of immunological tolerance, and modern approaches to the development of clinical trial programmes for such products. The analysis was based on scientific literature, as well as Russian and international guidelines, including the updated document of the European Medicines Agency. The paper presents clinical trial data on pharmacokinetics, efficacy, and safety of FVIII products, including data on manifestations of unwanted immunogenicity. It highlights molecular mechanisms of interaction between inhibitors and FVIII, and analyses the main factors (genetic characteristics, immune status of patients, dosage regimen, etc.) affecting the frequency and intensity of the immune response to the product. The authors summarised approaches to the clinical trial design, including selection of patients and studied parameters. They substantiate the need for post-authorisation studies to collect additional clinical data on both efficacy and safety of the routine use of the product, including additional assessment of immunogenicity and other adverse reactions. It is concluded that the successful use of high-quality FVIII products ensures by harmonisation of requirements of Russian and international regulatory documents.Постоянная заместительная терапия препаратами свертывания крови при гемофилии А может привести к серьезным осложнениям, одной из причин которых является развитие «нежелательного» иммунного ответа на лекарственный препарат фактора свертывания крови VIII (FVIII), что приводит к потере эффективности проводимой терапии. Цель работы — систематизация и обобщение сведений о проявлении нежелательной иммуногенности плазменных и рекомбинантных лекарственных препаратов FVIII, формировании иммунологической толерантности, о современных подходах к разработке программы проведения клинических исследований этих препаратов на основе данных литературы, а также международных и российских руководств, включая обновленный документ Европейского агентства по лекарственным средствам. В обзоре представлены данные об оценке в ходе клинических исследований препаратов FVIII фармакокинетики, эффективности и безопасности, в том числе проявлений нежелательной иммуногенности. Особое внимание уделено рассмотрению молекулярных механизмов взаимодействия ингибиторов и FVIII. Проанализированы основные факторы (генетические особенности, состояние иммунной системы пациента, режим дозирования препарата и др.), влияющие на частоту и выраженность иммунного ответа на препарат. Изложены подходы к дизайну клинических исследований, в том числе касающиеся отбора пациентов и выбора показателей для исследований. Обоснована необходимость пострегистрационных исследований с целью сбора дополнительных клинических данных, касающихся как эффективности, так и безопасности рутинного применения препарата, включая дополнительную оценку иммуногенности и других нежелательных реакций. Сделан вывод о том, что успешность внедрения в клиническую практику качественных лекарственных препаратов FVIII обеспечивается гармонизацией требований, изложенных в отечественных и международных нормативных документах